Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775695 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02775695 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 12 participants.
The verdict
NCT02775695, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a window-of-opportunity study that examines the efficacy of doxycycline, and FDA-approved oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic cancer following eight weeks of treatment.
Interventions
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2022-05-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775695
The ClinicalTrials.gov registry entry for NCT02775695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxycycline is the first listed.
NCT02775695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02775695 about?
NCT02775695 is a clinical study titled "Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer". This is a window-of-opportunity study that examines the efficacy of doxycycline, and FDA-approved oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic cancer following eight weeks of treatment.
What is the current status of trial NCT02775695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-04-03. Estimated completion is 2022-05-26.
What interventions are being tested in trial NCT02775695?
The interventions under investigation include: Doxycycline (DRUG).
Who is sponsoring clinical trial NCT02775695?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.